---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-23-000146"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:55:31.120644+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences Q3 revenue $61.5M (+66% YoY), raises FY2023 guidance to at least $200M

## Summary
- Q3 revenue $61.5M, up 66% YoY; adjusted revenue $60.6M, up 63%.
- Total test reports 18,409 (+52% YoY); DecisionDx-Melanoma 8,559 (+16%), TissueCypher 2,829 (+310%).
- Net loss narrowed to $(6.9)M from $(20.2)M; adjusted EBITDA $6.6M vs $(9.6)M.
- Raised FY2023 revenue guidance to at least $200M from at least $180M.
- Operating cash flow positive $5.0M; cash $229.8M.

## SEC filing metadata
- accession: 0001447362-23-000146
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000146/0001447362-23-000146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000146/cstl-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-23-000146
- JSON: https://secwatch.observer/filing/0001447362-23-000146.json
- Plain text: https://secwatch.observer/filing/0001447362-23-000146.txt

## Key facts
- Earnings Releases
  CASTLE BIOSCIENCES INC reported the third quarter ended September 30, 2023 results: revenue $61.5 million, net income $(6.9) million. Guidance raised.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $61.5 million
  - Net income: $(6.9) million
  - Guidance: raised
  - Result: reported results
  source text: Revenues were $61.5 million, a 66% increase compared to $37.0 million during the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000146/0001447362-23-000146-index.htm
- Earnings Releases
  CASTLE BIOSCIENCES INC reported the nine months ended September 30, 2023 results: revenue $153.7 million, net income $(54.9) million.
  - Period: the nine months ended September 30, 2023
  - Revenue: $153.7 million
  - Net income: $(54.9) million
  - Result: reported results
  source text: Revenues were $153.7 million, a 56% increase compared to $98.7 million during the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000146/0001447362-23-000146-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.